At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 582 enrolled
Drug / intervention
Nivolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
In Brief
A Phase 3 clinical trial evaluating Nivolumab and Docetaxel for Non-Squamous Cell Non-small Cell Lung Cancer. Completed, enrolled 582 participants across 119 sites in 22 countries.
Detailed Summary
The purpose of the study is to compare the overall survival of BMS-936558 (Nivolumab) as compared with Docetaxel in subjects with non-squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, Austria, Brazil, Canada, Chile, Czechia, France, Germany, Hong Kong, Hungary, Italy, Mexico, Norway, Peru, Poland, Romania, Russia, Singapore, Spain, Switzerland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartNov 2012
Primary CompletionFeb 2015
Study CompletionDec 2021
TodayJul 2026
First PostedAug 28, 2012
Enrollment StartNov 2, 2012
Primary CompletionFeb 5, 2015
Study CompletionDec 17, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.8 years ago
Interventions
Nivolumabbiological
Docetaxeldrug